Alzheimer’s researcher Donald Weaver tells The Conversation Weekly podcast what he’s learnt during more than 30 years of ...

The approval comes as two Alzheimer's drugs—lecanemab and donanemab—are already authorized by the FDA. Both are antibody therapies that target amyloid plaques and are believed to be more effective ...

Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

The tangled nerve fibers Dr. Alzheimer found are now known to be a result ... s Health Research to improve prevention, diagnosis, and treatment of conditions that affect women disproportionately.

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? Two ...

A drug that's been found to slow the progress of Alzheimer's disease by clearing proteins in the brain has been approved for ...

Dr Richard Oakley, director of research and innovation at the Alzheimer’s Society, said: “Results from this observational ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

HSV-1 infection may be linked to the risk for Alzheimer’s disease, but antiviral treatment may be protective, a large ...

TREATING cold sores with anti-viral medicines could slash the risk of Alzheimer’s disease by 17 per cent, research suggests. Previous studies have found that the herpes simplex virus – ...